HONOLULU, HAWAIIBiologics that move at the speed of emerging threats.
Koa Bio develops, scales, and deploys novel therapeutic biologics against multi-drug-resistant bacteria for military and civilian health.
THE CHALLENGEDrug-resistant bacteria are outpacing the antibiotics designed to stop them.
From battlefield wound infections to hospital-acquired outbreaks, multi-drug-resistant organisms threaten service members, veterans, and civilian populations worldwide. AMR is projected to cause 10 million deaths annually by 2050, and the pipeline of new antibiotics has not kept pace. Koa Bio exists to close that gap with a new class of biologic countermeasures designed for rapid deployment against the most dangerous bacterial threats.
HOW WE WORK01 Discover
Candidate biologics are generated using JURA Bio's Sovereign AI platform, which designs, builds, tests, and learns from billions of molecular candidates using manufacturing-aware generative models trained on real protein interaction data and real-time threat response.
02 Validate
Threat assessment and target determination are conducted in collaboration with scientists and physicians in theater and at the Walter Reed Army Institute of Research (WRAIR), ensuring that candidates are directed against the most operationally critical resistant strains.
03 Scale & Deploy
Koa Bio's core capability is taking validated candidates through rapid manufacturing scale-up and delivering them where they are needed most, bridging the gap between discovery and the point of care.
WHO WE WORK WITHKoa Bio works across government agencies, defense research institutions, AI-native drug discovery platforms, CROs & CMOs, clinical networks, and global health organizations to move novel biologics from concept to the point of need. Current partners include JURA Bio, AFRIMS, and the Walter Reed Army Institute of Research.